Teva- Pharmaceutical Industries Accounts Payable

As of the most recent data (June 2026), TEVA shows a accounts payable of $2.7B. That compares with $2.5B in the prior-year period — up 8.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TEVA's accounts payable is now $2.7B (was $2.5B) — a 8.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Teva- Pharmaceutical Industries is outperforming or lagging.

Tracking TEVA's accounts payable over time shows whether Teva- Pharmaceutical Industries is scaling, shrinking, or reshaping that part of the business. The current reading is $2.7B That compares with $2.5B in the prior-year period — up 8.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Teva- Pharmaceutical Industries's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $2.7B) with ownership activity and broader fundamentals.

Teva- Pharmaceutical Industries's accounts payable is $2.7B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.